Recent Research Analysts’ Ratings Changes for Tonix Pharmaceuticals (TNXP)

Several brokerages have updated their recommendations and price targets on shares of Tonix Pharmaceuticals (NASDAQ: TNXP) in the last few weeks:

• 5/4/2026 – Tonix Pharmaceuticals is now covered by TD Cowen. They set a “buy” rating and a $22.00 price target on the stock.
• 4/26/2026 – Tonix Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/20/2026 – Tonix Pharmaceuticals had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 4/18/2026 – Tonix Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/28/2026 – Tonix Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Activity at Tonix Pharmaceuticals

In other news, CEO Seth Lederman bought 15,000 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was bought at an average cost of $14.89 per share, for a total transaction of $223,350.00. Following the transaction, the chief executive officer owned 15,001 shares of the company’s stock, valued at $223,364.89. This represents a 1,500,000.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.00% of the company’s stock.

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.